These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15183074)

  • 1. Chronopharmacology of oxacalcitriol in 5/6 nephrectomized rats.
    Tsuruoka S; Nishiki K; Wakaumi M; Yamamoto H; Ando H; Ning W; Fujimura A
    Life Sci; 2004 Jul; 75(7):809-22. PubMed ID: 15183074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronopharmacology of oxacalcitriol in rat model of osteoporosis.
    Tsuruoka S; Wakaumi M; Yamamoto H; Fujimura A
    Eur J Pharmacol; 2004 Mar; 488(1-3):239-45. PubMed ID: 15044057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronotherapy with active vitamin D3 in aged stroke-prone spontaneously hypertensive rats, a model of osteoporosis.
    Tsuruoka S; Nishiki K; Sugimoto K; Fujimura A
    Eur J Pharmacol; 2001 Oct; 428(2):287-93. PubMed ID: 11675047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing time-dependent variation of bone resorption by cyclosporin A in rats' femurs.
    Tsuruoka S; Kaneda T; Maeda A; Ioka T; Fujimura A
    Eur J Pharmacol; 2007 Jun; 564(1-3):226-31. PubMed ID: 17362919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time of day improves efficacy and reduces adverse reactions of vitamin D3 in 5/6 nephrectomized rat.
    Tsuruoka S; Nishiki K; Sugimoto K; Fujimura A
    Life Sci; 2002 Aug; 71(15):1809-20. PubMed ID: 12151058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of diet to the dosing time-dependent change of vitamin D3-induced hypercalcemia in rats.
    Tsuruoka S; Sugimoto K; Fujimura A
    Life Sci; 2000 Dec; 68(5):579-89. PubMed ID: 11197755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion.
    Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E
    J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats.
    Hirata M; Endo K; Ohkawa H; Kumaki K; Kubodera N; Slatopolsky E; Kurokawa K; Fukagawa M
    Nephrol Dial Transplant; 2002; 17 Suppl 10():37-40. PubMed ID: 12386267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of 22-oxacalcitriol on serum calcitriol.
    Dusso AS; Negrea L; Finch J; Kamimura S; Lopez-Hilker S; Mori T; Nishii Y; Brown A; Slatopolsky E
    Endocrinology; 1992 Jun; 130(6):3129-34. PubMed ID: 1597134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
    Brown AJ; Ritter CR; Finch JL; Morrissey J; Martin KJ; Murayama E; Nishii Y; Slatopolsky E
    J Clin Invest; 1989 Sep; 84(3):728-32. PubMed ID: 2760211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
    Hirata M; Endo K; Katsumata K; Ichikawa F; Kubodera N; Fukagawa M
    Nephrol Dial Transplant; 2002; 17 Suppl 10():41-5. PubMed ID: 12386268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis.
    Hirata M; Katsumata K; Masaki T; Koike N; Endo K; Tsunemi K; Ohkawa H; Kurokawa K; Fukagawa M
    Kidney Int; 1999 Dec; 56(6):2040-7. PubMed ID: 10594779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,25-(OH)2-16ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect.
    Lippuner K; Perrelet R; Casez JP; Popp A; Uskokovic MR; Jaeger P
    Horm Res; 2004; 61(1):7-16. PubMed ID: 14646396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 22-Oxacalcitriol does not interfere with parathyroid hormone-induced phosphaturia or cyclic-AMP excretion.
    Friedlaender MM; Yagil Y; Wald H; Popovtzer MM
    Bone; 1995 Sep; 17(3):301-6. PubMed ID: 8541145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3.
    Hirata M; Katsumata K; Endo K; Fukushima N; Ohkawa H; Fukagawa M
    Nephrol Dial Transplant; 2003 Sep; 18(9):1770-6. PubMed ID: 12937223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3.
    Finch JL; Brown AJ; Mori T; Nishii Y; Slatopolsky E
    J Bone Miner Res; 1992 Jul; 7(7):835-9. PubMed ID: 1642151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing time-dependent variation in the hypocalcemic effect of calcitonin in rat.
    Nishiki K; Tsuruoka S; Wakaumi M; Yamamoto H; Koyama A; Fujimura A
    Eur J Pharmacol; 2003 Jan; 460(2-3):171-5. PubMed ID: 12559378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate depletion in the rat: effect of bisphosphonates and the calcemic response to PTH.
    Jara A; Lee E; Stauber D; Moatamed F; Felsenfeld AJ; Kleeman CR
    Kidney Int; 1999 Apr; 55(4):1434-43. PubMed ID: 10201008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism.
    Akizawa T; Ohashi Y; Akiba T; Suzuki M; Nishizawa Y; Ogata E; Slatopolsky E; Kurokawa K
    Ther Apher Dial; 2004 Dec; 8(6):480-91. PubMed ID: 15663548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.